The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Inclusion Criteria

• •1. Subject is 18 years or older of any gender or race
• •2. Subject is undergoing pars plana vitrectomy due to recurrent retinal detachment due to proliferative vitreoretinopathy or open globe injury
• •3. Subject is willing and able to provide written informed consent, comply with clinical trial procedures, and return for all clinical trial visits
• •4. Subjects of childbearing potential must agree to use two forms of birth control for the duration of the clinical trial